Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467174 | 0.88 | CA3 (0.74) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL10231803 | 0.86 | CA3 (0.86) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL1252712 | 0.86 | CA3 (0.86) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL13861685 | 0.83 | ALDH1A1 (0.79) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL2887269 | 0.81 | ALDH1A1 (0.56) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL3478019 | 0.80 | CA3 (0.42) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL993779 | 0.79 | EPHX1 (0.69) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL1387208 | 0.79 | — | — | |
| SCHEMBL6450550 | 0.78 | CA3 (0.73) | CA3CA5ACA5BALDH1A1SMN1; SMN2 | |
| SCHEMBL22851436 | 0.78 | ALDH1A1 (0.58) | CA3CA5ACA5BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022016195-A1 | PROCESSES FOR THE PREPARATION OF ARGINASE INHIBITORS AND THEIR SYNTHETIC INTERMEDIATES | INCYTE CORPORATION (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| EP-2063886-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | Adolor Corporation (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| CN-101184749-A | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORP (US) | 2008-05-21 | — | — | CN | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1871761-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006105442-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | CA3 1048/4885CA5A 2427/4885CA5B 2765/4885 |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | CA3 1168/4885CA5A 2117/4885CA5B 2640/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | CA3 395/4885CA5A 1614/4885CA5B 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.